Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 352 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sham Injection Procedure Clear all
Completed Phase 2 Interventional Results available

Darbepoetin Administration to Preterm Infants

NCT00334737
View directory record Official record
Conditions
Infant, Newborn
Interventions
Darbepoetin Alfa Injection, erythropoietin alfa injection, sham injection
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
1 Hour to 49 Hours
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Denver, Colorado • Ogden, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 28, 2026, 11:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Physical Exam, Static & Dynamic Ultrasound Assessment, & Treatment of Thoracolumbar Fascia (TLF) Mediated Low Back Pain

NCT06818175
View directory record Official record
Conditions
Low Back Pain, Chronic Low-back Pain, Acute Low Back Pain
Interventions
Ultrsound Guided Hydrodissection of the Thoracolumbar Fascia, Osteopathic Manipulative Treatment (OMT)
Procedure
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 28, 2026, 11:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema

NCT03397264
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aflibercept, OPT-302, Sham intravitreal injection
Biological · Other
Lead sponsor
Opthea Limited
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
34
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 28, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

NCT00509795
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
176
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 28, 2026, 11:14 AM EDT
Terminated Phase 2 Interventional Results available

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

NCT03267680
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion
Interventions
Cyclophosphamide, Indomethacin, IRX-2, Laboratory Biomarker Analysis, Multivitamin, Omeprazole, Placebo, Therapeutic Conventional Surgery
Drug · Biological · Other + 2 more
Lead sponsor
University of Southern California
Other
Eligibility
25 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 28, 2026, 11:14 AM EDT
Completed Phase 3 Interventional

Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes

NCT01421966
View directory record Official record
Conditions
Lower Extremity Chronic Ulcers in Diabetics
Interventions
CureXcell®, Sham injection
Biological
Lead sponsor
Macrocure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
31
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 28, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BIIB111 for the Treatment of Choroideremia

NCT03496012
View directory record Official record
Conditions
Choroideremia
Interventions
BIIB111
Genetic
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Male only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 28, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Platelet-Rich Plasma Therapy for Patellar Tendinopathy

NCT03136965
View directory record Official record
Conditions
Patellar Tendinitis
Interventions
PRP, Dry Needling, Dry Needling - Sham
Biological · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 39 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 28, 2026, 11:14 AM EDT
Recruiting Phase 2 Interventional

Local Anesthesia for Facial Fractures

NCT06429501
View directory record Official record
Conditions
Pain Management
Interventions
Bupivacaine/Epinephrine, Saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 28, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

NCT01429441
View directory record Official record
Conditions
Vitreomacular Adhesion Including Macular Hole
Interventions
Ocriplasmin, Sham injection
Drug · Other
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 28, 2026, 11:14 AM EDT
Completed Early Phase 1 Interventional

Single Injection Adductor Canal Block Versus Continuous Adductor Canal Infusion for Total Knee Arthroplasty

NCT02991404
View directory record Official record
Conditions
Total Knee Arthroplasty, Pain, Postoperative, Adductor Canal Block
Interventions
Multimodal Peripheral Nerve Block Injection, Single Shot Adductor Canal Block, Initial Bolus, Continuous infusion
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 28, 2026, 11:14 AM EDT
Terminated Not applicable Interventional Results available

Acupuncture for Pre-Procedure Anxiety

NCT03480919
View directory record Official record
Conditions
Anxiety
Interventions
Shen Men acupuncture, Epidural injection
Device · Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 28, 2026, 11:14 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

NCT04527107
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3, THR-149 0.13mg, THR-149 0.13mg + aflibercept 2mg, aflibercept 2mg + THR-149 0.13mg, Aflibercept 2mg
Drug
Lead sponsor
Oxurion
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 28, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

NCT02462928
View directory record Official record
Conditions
Macular Degeneration
Interventions
Abicipar Pegol, Ranibizumab, Sham Procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 28, 2026, 11:14 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

NCT07482176
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
79
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 28, 2026, 11:14 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Combining Stellate Ganglion Block With Prolonged Exposure for PTSD

NCT05889741
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Ropivacaine injection, Normal saline
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Fort Hood, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 28, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

NCT03038880
View directory record Official record
Conditions
Neovascularization, Choroidal, Macular Degeneration, Age-Related
Interventions
Faricimab, Ranibizumab, Sham Procedure
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 28, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls

NCT01169103
View directory record Official record
Conditions
Obesity
Interventions
recombinant human growth hormone (rhGH), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 28, 2026, 11:14 AM EDT
Terminated Phase 2Phase 3 Interventional

Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT02341560
View directory record Official record
Conditions
Non Arteritic Anterior Ischemic Optic Neuropathy
Interventions
QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg, Sham Injection Procedure
Drug · Other
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
44
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 28, 2026, 11:14 AM EDT
Recruiting Not applicable Interventional

EUS-guided Celiac Plexus Block vs. Sham in Chronic Pancreatitis

NCT06178315
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
EUS-guided celiac plexus block, Sham procedure
Procedure
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 28, 2026, 11:14 AM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

NCT03203447
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 28, 2026, 11:14 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The PAIN (Pelvic Area Injection for Numbness) Study

NCT05972681
View directory record Official record
Conditions
Vaginal Laceration During Delivery
Interventions
Bupivacaine, Epinephrine, Sham normal saline arm
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 28, 2026, 11:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05769153
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
42
States / cities
Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 28, 2026, 11:14 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Pectoral Blocks on Perioperative Pain in Gender Affirmation Top Surgery

NCT04474366
View directory record Official record
Conditions
Gender Dysphoria, Opioid Use, Pain, Postoperative
Interventions
Ropivacaine 0.2% Injectable Solution, Saline (0.9%)
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 28, 2026, 11:14 AM EDT